Sunday 18 October 2026
Export EVAX’s income statement to Excel — free account
Evaxion A/S - Sponsored ADR
EVAX Healthcare Biotechnology
Evaxion A/S - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, up 125.1% from fiscal 2024. In the quarter to June 2026, revenue grew 14,590.2%, EPS fell 72.4% and free cash flow fell 56.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
2.83
0.03
+1.07%
Follow EVAX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | — | — | 2.24 | |
P/FCF ratio |
— | — | — | 0.00 | |
P/Operating CF |
— | — | — | (3.10) | |
P/B ratio |
— | — | — | 1.44 | |
Price to Tangible BV |
— | — | — | 1.45 | |
EV/Sales |
— | — | — | 2.27 | |
EV/EBITDA |
— | — | — | 0.00 | |
EV/Operating CF |
— | — | — | (0.81) | |
EV/FCF |
— | — | — | (0.79) | |
Quick Ratio |
4.74 | 0.00 | 5.66 | 0.00 | |
Current Ratio |
5.06 | 0.00 | 5.85 | 0.00 | |
Net Debt/EBITDA |
1.88 | 0.00 | 0.00 | (3.50) | |
Debt/Assets |
34.85% | 0.00% | 25.15% | 0.00% | |
Debt/Equity |
0.71 | 0.00 | 0.42 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.50 | |
Operating CF/Net income |
2.22 | 0.00 | — | 0.00 | |
Capex/Depreciation |
0.00 | — | — | — | |
Interest Coverage |
(16.44) | (11.50) | — | 2.22 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | — | 41.27% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | — | 18.38% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | — | — | 0.00% | |
Graham Net Nets |
— | — | — | (0.11) | |
Graham Number |
— | — | — | 0.00 | |
Earnings Yield |
— | — | — | (55.08%) | |
Free Cash Flow Yield |
— | — | — | (127.97%) | |
Revenue per Share |
0.00 | 0.00 | — | 1.18 | |
Operating CF per Share |
(1.11) | 0.00 | — | 0.00 | |
Capex per Share |
0.00 | 0.00 | — | 0.00 | |
Free Cash Flow per Share |
(1.11) | 0.00 | — | 0.00 | |
Cash per Share |
1.88 | 2.21 | 0.00 | 1.66 | |
Shareholders Equity per Share |
1.28 | 1.58 | 0.00 | 2.61 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.28 | 1.58 | 0.00 | 2.61 | |
Free Cash Flow |
(8.26) | — | — | — | |
Working Capital |
12.73 | 18.44 | 20.64 | 10.57 | |
Net Current Asset Value |
6.01 | 8.01 | 13.53 | (2.57) | |
EV/EBIT |
— | — | — | 0.00 | |
Capex to Sales |
— | — | — | 0.00 | |
Price to Operating Income |
— | — | — | 0.00 | |
| Other line items | |||||
Average Receivables |
0.81 | — | 0.84 | — | |
Average Payables |
2.08 | — | 2.44 | — | |
Average Assets |
20.91 | 18.06 | 21.82 | 21.31 | |
Average Common Equity |
7.88 | 11.76 | 7.69 | 8.34 |
Columns are period end dates